Maximizing Tobacco Product Potential to Reduce Smoking in Indonesia

Regulations by 2FIRSTS.ai
Apr.02.2024
Maximizing Tobacco Product Potential to Reduce Smoking in Indonesia
Indonesia's vaping retailers association urges government to maximize tobacco alternatives to reduce smoking rates, citing successful global examples.

According to a report by Antaranews on April 1st, the Indonesian E-cigarette Retail Association (Asosiasi Ritel Vape Indonesia) has called on the government to maximize the potential of its tobacco products in order to reduce the number of smokers in Indonesia. Statistics show that from 1995 to 2018, the prevalence of smoking in Indonesia has surged to 36.3%, with approximately 69.1 million people.

 

The president of the association, Arvindo Fachmi Kurnia Firmansyah, stated that e-cigarettes and heated tobacco products are a more effective choice for adult smokers. In February 2024, a study from the University of Bern published in the New England Journal of Medicine found that the use of alternative tobacco products had a 21% impact on successful smoking cessation. Among those who used alternative tobacco products, the success rate of quitting smoking reached 53%. In contrast, the success rate of quitting smoking was only 32% among those who did not fully utilize alternative tobacco products.

 

Currently, England and Sweden have successfully reduced the number of smokers by supporting the use of alternative tobacco products. According to a report from the UK's Office for National Statistics, the smoking rate in the UK in 2022 was 12.9%, approximately 6.4 million people, a decrease of 200,000 from 13.3% in 2021. Sweden, as the first smoke-free country in Europe, has a smoking rate of only 5.16%, significantly lower compared to 11% in 2015.

 

Alex Wodak, former director of alcohol and drug services at St. Vincent's Hospital in Australia, suggests that people can reduce the risks of smoking by using alternative tobacco products and practicing the concept of harm reduction.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
KT&G Integrates “lil Aible” Dedicated Stick Lineup Under the “AIIM” Brand
KT&G Integrates “lil Aible” Dedicated Stick Lineup Under the “AIIM” Brand
KT&G said it will integrate the Real, Granular and Vapor Stick product lines for its heated tobacco device “lil Aible” under the “AIIM” brand. The company said the brand integration is intended to organize the existing lineup more intuitively and improve consumer accessibility and convenience.
Mar.18 by 2FIRSTS.ai
UK OPSS launches vape safety campaign focusing on use, charging and disposal
UK OPSS launches vape safety campaign focusing on use, charging and disposal
The UK Office for Product Safety and Standards (OPSS) published information on March 4, 2026, launching a new campaign to raise awareness among young people about safety issues linked to using, charging and disposing of vapes.
Mar.06 by 2FIRSTS.ai
PMI U.S. to Host Job Fair for ZYN Nicotine Pouch Factory in Colorado
PMI U.S. to Host Job Fair for ZYN Nicotine Pouch Factory in Colorado
PMI U.S. plans to host a job fair to recruit employees for its ZYN nicotine pouch manufacturing facility currently under construction in Aurora, Colorado. The main position being recruited is Process Technician, responsible for equipment operation and maintenance, quality and safety monitoring, and supporting continuous production improvements.
Mar.12 by 2FIRSTS.ai
JTI appoints Olesja Flores as General Manager for Global Travel Retail
JTI appoints Olesja Flores as General Manager for Global Travel Retail
Japan Tobacco International (JTI) has appointed veteran executive Olesja Flores as General Manager, Global Travel Retail. Flores, who has spent more than 25 years at JTI and most recently served as General Manager for the Swiss market, will be based in Dubai and oversee the company’s global travel retail business.
Jan.23 by 2FIRSTS.ai
Fontem Sues FDA Over Refusal-to-File Decision for Nicotine Pouch PMTAs
Fontem Sues FDA Over Refusal-to-File Decision for Nicotine Pouch PMTAs
According to a complaint filed on March 17 in the U.S. District Court for the Northern District of Texas, Fontem US, LLC and Texas retailer OM Investment, LLC sued the Food and Drug Administration and the Department of Health and Human Services over FDA’s refusal-to-file decision for certain Zone nicotine pouch PMTAs.
Mar.19 by 2FIRSTS.ai